Upstream Bio (UPB) Current Assets (2023 - 2026)

Upstream Bio's Current Assets history runs 4 years deep, the most recent figure standing at $316.3 million for Q1 2026.

• On a quarterly basis, Current Assets fell 30.3% year-over-year to $316.3 million in Q1 2026; TTM through Mar 2026 was $316.3 million, a 30.3% decrease from a year earlier, with the FY2025 full-year figure at $351.8 million, down 26.58% from the prior year.
• Current Assets retreated to $316.3 million in Q1 2026 per UPB's latest filing, from $351.8 million in the prior quarter.
• Across five years, Current Assets topped out at $479.2 million in Q4 2024 and bottomed at $117.0 million in Q4 2023.
• The 4-year median for Current Assets is $370.4 million (2025), against an average of $344.1 million.
• Across the five-year window, Current Assets soared 309.55% in 2024 and slumped 30.3% in 2026, its largest moves.
• Year by year, Current Assets stood at $117.0 million in 2023, then surged by 309.55% to $479.2 million in 2024, then declined by 26.58% to $351.8 million in 2025, then retreated by 10.1% to $316.3 million in 2026.
• Per Business Quant, the three latest UPB Current Assets figures stand at $316.3 million (Q1 2026), $351.8 million (Q4 2025), and $389.0 million (Q3 2025).